Research programme: immune therapeutics - Eisai Andover innovative Medicines (AiM) InstituteAlternative Names: AiM institute immune therapeutics
Latest Information Update: 21 Sep 2016
At a glance
- Originator Eisai Andover Innovative Medicines Institute
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Brain disorders; Cancer; Immunological disorders
Most Recent Events
- 15 Sep 2016 Early research in Immunological disorders, Cancer and Brain disorders in USA